These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750 [TBL] [Abstract][Full Text] [Related]
5. Cutaneous Mycobacterium haemophilum infection in a patient receiving infliximab for psoriasis. Aslam A; Green RL; Motta L; Ghrew M; Griffiths CE; Warren RB Br J Dermatol; 2013 Feb; 168(2):446-7. PubMed ID: 22816532 [No Abstract] [Full Text] [Related]
6. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139 [TBL] [Abstract][Full Text] [Related]
7. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Danko JR; Gilliland WR; Miller RS; Decker CF Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397 [TBL] [Abstract][Full Text] [Related]
8. Rare infection in patient with rheumatoid arthritis treated with adalimumab. Kapur N; Ghai R; Block JA; Khandelwal S BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31753822 [No Abstract] [Full Text] [Related]
9. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769 [TBL] [Abstract][Full Text] [Related]
10. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lee SK; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990 [TBL] [Abstract][Full Text] [Related]
11. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [TBL] [Abstract][Full Text] [Related]
12. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Curtis JR; Xie F; Chen L; Muntner P; Grijalva CG; Spettell C; Fernandes J; McMahan RM; Baddley JW; Saag KG; Beukelman T; Delzell E Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1480-9. PubMed ID: 22833479 [TBL] [Abstract][Full Text] [Related]
13. The yin and yang of tumor necrosis factor inhibitors. Calabrese L Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447 [TBL] [Abstract][Full Text] [Related]
15. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
17. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
18. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP; Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999 [TBL] [Abstract][Full Text] [Related]
19. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557 [TBL] [Abstract][Full Text] [Related]
20. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Williams VL; Cohen PR Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]